{"organizations": [], "uuid": "a93de490e8634d7198a317cee7ba6f418f8787bb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-pfizer-announces-positive-top-line/brief-pfizer-announces-positive-top-line-results-for-potential-biosimilar-to-rituxan-mabthera-idUSFWN1PJ11B", "country": "US", "domain_rank": 408, "title": "BRIEF-Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/Mabthera", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-24T15:46:00.000+02:00", "replies_count": 0, "uuid": "a93de490e8634d7198a317cee7ba6f418f8787bb"}, "author": "", "url": "https://www.reuters.com/article/brief-pfizer-announces-positive-top-line/brief-pfizer-announces-positive-top-line-results-for-potential-biosimilar-to-rituxan-mabthera-idUSFWN1PJ11B", "ord_in_thread": 0, "title": "BRIEF-Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/Mabthera", "locations": [], "entities": {"persons": [{"name": "pote", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "pfizer inc", "sentiment": "none"}, {"name": "pfizer", "sentiment": "none"}, {"name": "pfizer inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 24, 2018 / 1:48 PM / in 10 minutes BRIEF-Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan/Mabthera Reuters Staff \nJan 24 (Reuters) - Pfizer Inc: \n* PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN®/MABTHERA® \n* PFIZER INC - PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FOR POTENTIAL BIOSIMILAR TO RITUXAN(®)/MABTHERA(®) \n* PFIZER INC - RESULTS FROM COMPARATIVE REFLECTIONS B3281006 STUDY DEMONSTRATE EQUIVALENCE IN PATIENTS WITH INDOLENT FOLLICULAR LYMPHOMA \n* PFIZER INC - REFLECTIONS B3281006, A COMPARATIVE SAFETY AND EFFICACY STUDY OF PF-05280586 VERSUS MABTHERA(®) (RITUXIMAB-EU), MET ITS PRIMARY ENDPOINT \n* PFIZER - TRIAL DEMONSTRATED EQUIVALENCE IN OVERALL RESPONSE RATE FOR FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-24T15:46:00.000+02:00", "crawled": "2018-01-24T16:02:12.014+02:00", "highlightTitle": ""}